Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009

Gynecologic Oncology

Volumn 112, Issue 3, 2009, Pages 444-449

  Tiersten, Amy D ^a   Liu, P Y ^b   Smith, Harriet O ^c   Wilczynski, Sharon P ^d   Robinson III, William R ^e   Markman, Maurie ^f   Alberts, David S ^g  

^a NEW YORK UNIVERSITY   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Harrington Cancer Center   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

Author keywords

Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CATHETER INFECTION; COMPARATIVE STUDY; CYTOLOGY; CYTOREDUCTIVE SURGERY; DRUG WITHDRAWAL; EPITHELIAL OVARIAN CANCER; EPITHELIUM TUMOR; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT INFECTION; SEPSIS; THROMBOCYTOPENIA; TUMOR BIOPSY; UTERINE TUBE CARCINOMA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 60449103699     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.10.028     Document Type: Article

References (35)

1. Hoskins W.J., Bundy B.N., Thigpen J.T., et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47 (1992) 159-166
2. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-980
3. Heintz A.P.M., Van Oosterom A.T., Trimbos J.B.M.C., et al. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol. Oncol. 30 (1988) 347-358
4. Burghardt E., Girardi F., Lahousen M., et al. Patterns of pelvic and para-aortic lymph node involvement in ovarian cancer. Gynecol. Oncol. 40 (1991) 103-106
5. Friedlander M.L., Hedley D.W., Swanson C., et al. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J. Clin. Oncol. 6 (1988) 282-290
6. Hacker N.F., Berek J.S., Lagasse L.D., et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61 (1983) 413-420
7. Van der Burg M.E., van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecologic Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. NEJM 332 (1995) 629-634
8. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. NEJM 351 24 (2004) 2489-2497
9. Chambers J.T., Chambers S.K., Voynick I.M., et al. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol. Oncol. 37 (1990) 327-331
10. Schwartz P.E., Chambers J.T., and Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol. Oncol. 53 (1994) 33-37
11. Surwit E., Childers J., Atlas I., et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int. J. Gynecol. Cancer. 6 (1996) 356-361
12. Schwartz P.E., Rutherford T.J., Chambers J.T., et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol. Oncol. 72 (1999) 93-99
13. Jacob J.H., Gershenson D.M., Morris M., et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 42 (1991) 146-150
14. Lim J.T.W., and Green J.A. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin. Oncol. R. Coll. Radiol. 5 (1993) 198-202
15. Vergote I., De Wever I., Tjalma W., et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71 (1998) 431-436
16. Kumar L., Hariprasad R., Kumar S., et al. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): A prospective randomized study-Interim results. J. Clin. Oncol. 25 (2007) 18s (suppl; abstr 5531)
17. Kuhn W., Rutke S., Späthe K., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 10 (2001) 2585-2591
18. Nelson B.E., Rosenfield A.T., and Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol. 11 (1993) 166-172
19. Schneider J.G. Intraperitoneal chemotherapy. Obstet. Gynecol. Clin. North Am. 21 (1994) 195-212
20. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. NEJM 335 (1996) 1950-1956
21. Markman M., Bundy B., Alberts D., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
22. Markman M., Rowinsky E., Hakes T., et al. Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J. Clin. Oncol. 10 (1992) 1485-1491
23. Francis P., Rowinsky E., Schneider J., et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J. Clin. Oncol. 13 (1995) 2961-2967
24. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
25. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7 (1989) 1748-1756
26. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer. NEJM 334 (1996) 1-6
27. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18 (2000) 106-115
28. Risum S., Høgdall C., Loft A., et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography-A prospective study. Gynecol. Oncol. 108 (2008) 265-270
29. Salani R., Axtell A., Gerardi M., et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 108 (2008) 271-275
30. Bristow R., Eisenhauer E., Santillan A., et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol. Oncol. 104 (2007) 480-490
31. DeGregorio M.W., Lum B.L., Holleran W.M., et al. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother. Pharmacol. 18 (1986) 235-238
32. Elferink F., van der Vijgh W.J.F., Klein I., et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol. 21 (1988) 57-60
33. Speyer J.L., Beller U., Colombo N., et al. Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J. Clin. Oncol. 8 (1990) 1335-1341
34. Pfeiffer P., Bennedbaek O., and Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol. Oncol. 36 (1990) 306-311
35. Fujiwara K., Markman M., Morgan M., et al. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol. Oncol. 97 (2005) 10-15